Skip to main content

BIO-TECHNE Corp company profile

  • TECH · Nasdaq
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$72.80−0.05%Close 13 Nov 2026

About BIO-TECHNE Corp

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. It operates two segments. Protein Sciences, which represents approximately 72% of net sales in fiscal 2026, supplies biological reagents, proteomic analytical tools and immunoassays to academic researchers, pharmaceutical and biotech companies, and contract research organizations. Diagnostics and Spatial Biology, representing approximately 28% of net revenues, provides diagnostic controls, calibrators and assays, spatial biology instruments and in-situ hybridization assays, and genetic and oncology kits. The company sells directly and through distributors and OEM agreements, primarily in North America, Europe and China, and manufactures most of its products in North America, the U.K., Canada, Switzerland and China.

A summary of the business section of the company's latest annual report, filed 24 Aug 2026.

Company facts

TickerTECH · Nasdaq
SectorBiotechnology
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends30 June
Reporting currencyUSD
CIK842023
Latest annual report10-K, filed 24 Aug 2026

Officers and directors

NameRoleShares ownedLatest Form 4
James HippelCFO589K · 0.4%Option exercise, 15 Aug 2026
Kim KeldermanChief Executive Officer · Director378K · 0.2%Option exercise, 15 Aug 2026
John L. HigginsDirector129K · 0.1%Option exercise, 28 Sep 2026
Robert V. BaumgartnerDirector108K · 0.1%Option exercise, 22 Sep 2026
Roeland Nusse, Ph.D.Director108K · 0.1%Option exercise, 25 Aug 2025
William GeistPRESIDENT, PROTEIN SCIENCES69.6K · 0%Option exercise, 15 Aug 2026
Joseph Keegan, Ph.D.Director61.4K · 0%Grant or award, 30 Oct 2025
Shane BohnenSVP - General Counsel41.8K · 0%Shares withheld for tax, 15 Aug 2026
Alpna Seth, Ph.D.Director41.3K · 0%Grant or award, 30 Oct 2025
Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhilDirector39.2K · 0%Grant or award, 30 Oct 2025
Julie L. BushmanDirector28.0K · 0%Grant or award, 30 Oct 2025
Matthew McManusPresident - Diag & Spatial Bio14.0K · 0%Option exercise, 1 Feb 2026
Dr. Judith KlimovskyDirector7.3K · 0%Grant or award, 30 Oct 2025
Dr. Amy HerrDirector1.3K · 0%Option exercise, 15 Aug 2026
Crouse Steven C.President - Diag & Spatial Bi—Shares withheld for tax, 15 Aug 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

TECH in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.